Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Irofulven hydroxymethylacylfulvene: Phase II

In a Phase II study in 52 evaluable patients with hormone-refractory prostate

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE